Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07000136 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
A Phase 3 study of Heterozygous Familial Hypercholesterolaemia, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 455
- Enrollment target
- 20
- Study locations
NCT07000136 is a Phase 3 study of Heterozygous Familial Hypercholesterolaemia that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 455 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT07000136, a Phase 3 study of Heterozygous Familial Hypercholesterolaemia, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 455 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study to evaluate the efficacy and safety of AZD0780 in adults with HeFH and elevated LDL-C, either with clinical ASCVD and LDL-C levels of 55 mg/dL or higher or without clinical ASCVD and LDL-C levels of 70 mg/dL or higher. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will be up to approximately 56 weeks, including a screening period of up to 14 days, treatment with AZD0780 or placebo for 52 weeks, and a safety follow-up period of 10 days.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD0780
Study Locations (20)
Texas
- Research Site - Houston
- Research Site - Humble
- Research Site - Kingwood
- Research Site - McAllen
- Research Site - Mesquite
California
- Research Site - Garden Grove
- Research Site - San Diego
Florida
- Research Site - Hialeah
- Research Site - Orlando
Ohio
- Research Site - Cincinnati
- Research Site - Lima
Georgia
- Research Site - Peachtree Corners
Illinois
- Research Site - Chicago
Louisiana
- Research Site - Hammond
Nevada
- Research Site - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2025-06-10 |
| Est. Completion | 2027-01-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07000136
The ClinicalTrials.gov registry entry for NCT07000136 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 455 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heterozygous Familial Hypercholesterolaemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07000136 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT07000136 about?
NCT07000136 is a clinical study titled "A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH". This is a study to evaluate the efficacy and safety of AZD0780 in adults with HeFH and elevated LDL-C, either with clinical ASCVD and LDL-C levels of 55 mg/dL or higher or without clinical ASCVD and LDL-C levels of 70 mg/dL or higher. AZD0780 is a small molecule that reduces the amount of LDL-C in t...
What is the current status of trial NCT07000136?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 455 participants. The study started on 2025-06-10. Estimated completion is 2027-01-04.
What conditions does trial NCT07000136 study?
This clinical trial studies the following conditions: Heterozygous Familial Hypercholesterolaemia.
What interventions are being tested in trial NCT07000136?
The interventions under investigation include: Placebo (DRUG), AZD0780 (DRUG).
Who is sponsoring clinical trial NCT07000136?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07000136 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.